Institution
University of Milano-Bicocca
Education•Milan, Italy•
About: University of Milano-Bicocca is a education organization based out in Milan, Italy. It is known for research contribution in the topics: Population & Blood pressure. The organization has 8972 authors who have published 22322 publications receiving 620484 citations. The organization is also known as: Università degli Studi di Milano-Bicocca & Universita degli Studi di Milano-Bicocca.
Topics: Population, Blood pressure, Large Hadron Collider, Branching fraction, Ambulatory blood pressure
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This chapter examines the main mechanisms of obesity and obesity‐related hypertension and in particular the role of sympathetic nervous system, the alterations of the renal function and at the microvascular level, and depicts therole of insulin resistance as factor stimulating and potentiating the other mechanisms.
450 citations
••
University of Milan1, Spanish National Research Council2, University of Parma3, University of Bern4, University of Helsinki5, University of Düsseldorf6, Bangor University7, University of Kiel8, University of Natural Resources and Life Sciences, Vienna9, National University of Ireland, Galway10, University of Florence11, University College Dublin12, University of Milano-Bicocca13, Utrecht University14, Joseph Fourier University15, University of Seville16, University of Leeds17, Maynooth University18, Claude Bernard University Lyon 119, Université de Namur20, Wageningen University and Research Centre21, King Abdulaziz University22, University of Grenoble23
TL;DR: By interfering with pathogen adhesion, such glycocompounds including glycopolymers, glycoclusters, glycodendrimers and glyconanoparticles have the potential to improve or replace antibiotic treatments that are now subverted by resistance.
Abstract: Multivalency plays a major role in biological processes and particularly in the relationship between pathogenic microorganisms and their host that involves protein-glycan recognition. These interactions occur during the first steps of infection, for specific recognition between host and bacteria, but also at different stages of the immune response. The search for high-affinity ligands for studying such interactions involves the combination of carbohydrate head groups with different scaffolds and linkers generating multivalent glycocompounds with controlled spatial and topology parameters. By interfering with pathogen adhesion, such glycocompounds including glycopolymers, glycoclusters, glycodendrimers and glyconanoparticles have the potential to improve or replace antibiotic treatments that are now subverted by resistance. Multivalent glycoconjugates have also been used for stimulating the innate and adaptive immune systems, for example with carbohydrate-based vaccines. Bacteria present on their surfaces natural multivalent glycoconjugates such as lipopolysaccharides and S-layers that can also be exploited or targeted in anti-infectious strategies.
449 citations
••
TL;DR: Combined use of low-dose spiral CT and selective PET effectively detects early lung cancer in high-risk individuals in a large cohort of high- risk volunteers.
447 citations
••
Charité1, Amgen2, University of Tübingen3, Goethe University Frankfurt4, Boston Children's Hospital5, University of Düsseldorf6, University of Pavia7, University of Milano-Bicocca8, University of Padua9, Erasmus University Rotterdam10, University of Pennsylvania11, Cincinnati Children's Hospital Medical Center12, Children's Hospital Los Angeles13, Children's Hospital of Philadelphia14, Seattle Children's15, Primary Children's Hospital16, Harvard University17, University of Colorado Denver18, University of Toronto19
TL;DR: This trial, which to the best of the authors' knowledge was the first such trial in pediatrics, demonstrated antileukemic activity of single-agent blinatumomab with complete minimal residual disease response in children with relapsed/refractory BCP-ALL.
Abstract: Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Methods This open-label study enrolled children < 18 years old with relapsed/refractory BCP-ALL in a phase I dosage-escalation part and a phase II part, using 6-week treatment cycles. Primary end points were maximum-tolerated dosage (phase I) and complete remission rate within the first two cycles (phase II). Results We treated 49 patients in phase I and 44 patients in phase II. Four patients had dose-limiting toxicities in cycle 1 (phase I). Three experienced grade 4 cytokine-release syndrome (one attributed to grade 5 cardiac failure); one had fatal respiratory failure. The maximum-tolerated dosage was 15 µg/m2/d. Blinatumomab pharmacokinetics was linear across dosage levels and consistent among age groups. On the basis of the phase I data, the recommended blinatumomab dosage for children with relapsed/refractory ALL was 5 µg/m2/d for the first 7 days, followed by 15 µg/m2/d thereafter. Among the 70 patients who received the recommended dosage, 27 (39%; 95% CI, 27% to 51%) achieved complete remission within the first two cycles, 14 (52%) of whom achieved complete minimal residual disease response. The most frequent grade ≥ 3 adverse events were anemia (36%), thrombocytopenia (21%), and hypokalemia (17%). Three patients (4%) and one patient (1%) had cytokine-release syndrome of grade 3 and 4, respectively. Two patients (3%) interrupted treatment after grade 2 seizures. Conclusion This trial, which to the best of our knowledge was the first such trial in pediatrics, demonstrated antileukemic activity of single-agent blinatumomab with complete minimal residual disease response in children with relapsed/refractory BCP-ALL. Blinatumomab may represent an important new treatment option in this setting, requiring further investigation in curative indications.
446 citations
••
TL;DR: This is the most precise measurement of R_{K} to date and is compatible with the standard model at the level of 2.5 standard deviations.
Abstract: A measurement of the ratio of branching fractions of the decays
B
+
→
K
+
μ
+
μ
−
and
B
+
→
K
+
e
+
e
−
is presented. The proton-proton collision data used correspond to an integrated luminosity of
5.0
fb
−
1
recorded with the LHCb experiment at center-of-mass energies of 7, 8, and 13 TeV. For the dilepton mass-squared range
1.1
<
q
2
<
6.0
GeV
2
/
c
4
the ratio of branching fractions is measured to be
R
K
=
0.84
6
+
0.060
−
0.054
+
0.016
−
0.014
, where the first uncertainty is statistical and the second systematic. This is the most precise measurement of
R
K
to date and is compatible with the standard model at the level of 2.5 standard deviations.
446 citations
Authors
Showing all 9226 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carlo Rovelli | 146 | 1502 | 103550 |
Giuseppe Mancia | 145 | 1369 | 139692 |
Marco Bersanelli | 142 | 526 | 105135 |
Teruki Kamon | 142 | 2034 | 115633 |
Marco Colonna | 139 | 512 | 71166 |
M. I. Martínez | 134 | 1251 | 79885 |
A. Mennella | 132 | 463 | 93236 |
Roberto Salerno | 132 | 1197 | 83409 |
Federico Ferri | 132 | 1376 | 89337 |
Marco Paganoni | 132 | 1438 | 88482 |
Arabella Martelli | 131 | 1318 | 84029 |
Sandra Malvezzi | 129 | 1326 | 84401 |
Andrea Massironi | 129 | 1115 | 78457 |
Marco Pieri | 129 | 1285 | 82914 |
Cristina Riccardi | 129 | 1627 | 91452 |